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A B S T R A C T
In Barrett associated tumorigenesis, oxidative phosphorylation and glycolysis are reprogrammed early
in the disease sequence and act mutually to promote disease progression. However, the link between
energy metabolism and its connection with other central cellular processes within the Barrett microen-
vironment is unknown. The aim of this study was to examine the relationship betweenmetabolism (ATP5B/
GAPDH), hypoxia (HIF1α), inﬂammation (IL1β/SERPINA3), p53 and obesity status using in-vivo and ex-
vivo models of Barrett oesophagus. At the protein level, ATP5B (r = 0.71, P < 0.0001) and p53 (r = 0.455,
P = 0.015) were found to be strongly associatedwith hypoxia. In addition, levels of ATP5B (r = 0.53, P = 0.0031)
and GAPDH (r = −0.39, P = 0.0357) were positively associated with p53 expression. Moreover, we dem-
onstrate that ATP5B (r = 0.8, P < 0.0001) and GAPDH (r = 0.43, P = 0.022) were positively associated with
IL1β expression. Interestingly, obesity was negatively associatedwith oxidative phosphorylation (r = −0.6016,
P = 0.0177) but positively associated with glycolysis (r = 0.743, P = 0.0015). Comparable correlations were
exhibited in the ex-vivo explant tissue between metabolism, p53, hypoxia, inﬂammation and angiogen-
esis (P < 0.05). We have shown that metabolism is closely linked withmany cellular processes in the Barrett
tissue microenvironment.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Barrett oesophagus is an inﬂammatory preneoplastic lesion
deﬁned as a condition in which the normal stratiﬁed squamous ep-
ithelium of the oesophagus is replaced by metaplastic columnar
epithelium, speciﬁcally specialised intestinal metaplasia (SIM) [1].
Barrett oesophagus arises from chronic gastroesophageal reﬂux
disease (GORD) of acid and bile, and can progress to oesophageal
adenocarcinoma (OAC) through low-grade dysplasia (LGD) and high-
grade dysplasia (HGD) [2,3]. The annual risk of OAC in individuals
with Barrett oesophagus is approximately 0.12% [2]. At this time,
no established biomarker has been uncovered to establish risk and
patients undergo regular surveillance endoscopy with multiple bi-
opsies to assess LGD or HGD. The medical management is
predominantly acid suppression therapy with proton pump inhibi-
tors, and no therapies that target the immune or inﬂammatory
environment have been developed [4,5].
It is established that key cellular processes, with distinctive func-
tional roles, are involved in promoting disease progression in Barrett
oesophagus. Some of these processes include inﬂammation, hypoxia
and angiogenesis [6–12]. Hypoxia, mediated through hypoxia-
inducible factor-1 alpha (HIF1α), is associated with the inﬂammatory
reaction in Barrett oesophagus, however, little is known on how it
links with other cellular mediators [7]. Increased HIF1α and HIF2α
expression has been demonstrated across themetaplastic-dysplastic-
OAC sequence [6]. Barrett-associated inﬂammation, through
canonical pro-inﬂammatory mediators such as interleukin-6 (IL6),
IL1β and signal transducer and activator of transcription 3 (STAT3),
has additionally been shown to exacerbate inﬂammation and
promote OAC [9,11]. A recent study showed that neoplastic and non-
neoplastic Barrett cells expressing vascular endothelial growth factor
(VEGF) and VEGFR2 mRNA and protein, promoted cell prolifera-
tion through a phospholipase C gamma1-protein kinase C-ERK
pathway subsequent to VEGF-VEGFR2 activation [12]. Moreover,
sunitinib-induced VEGF inhibition reduced the weight and
volume inmouse xenografts tumours from transformed Barrett cells
[12].
Obesity has further been implicated in disease progression in
Barrett oesophagus [13,14]. Individuals with central or visceral
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obesity, measured by waist circumferences, are at an increased risk
of developing Barrett oesophagus [13]. Furthermore, individuals with
a greater propensity to obesity have higher risks of intestinal meta-
plasia, thereby showing that obesity is independently associatedwith
Barrett oesophagus and its subsequent progression to OAC [14]. Epi-
demiological studies have also shown a link between leptin and
reduced adiponectin, both characteristic of obesity and Barrett oe-
sophagus [15–18]. However, how obesity and associated changes
in adipokines, cytokines, insulin and IGF1-axis, immune mecha-
nisms and their downstream signalling pathways inﬂuences Barrett
oesophagus and Barrett tumorigenesis at the cellular level is cur-
rently unknown.
Alterations in energy metabolism is one of the new emerging
hallmarks of cancer and disease progression [19,20]. Previous re-
search from our group has demonstrated that both oxidative
phosphorylation and glycolysis are reprogrammed early in the in-
ﬂamed Barrett disease sequence and may act mutually to promote
disease progression in Barrett oesophagus [21]. In addition, levels
of ATP5B, a marker of oxidative phosphorylation, in ﬁrst time sur-
veillance biopsymaterial, segregated Barrett patients who progressed
to HGD/OAC from non-progressors, highlighting the possible
prognostic advantage of assessing metabolic proﬁles in these
preneoplastic patients [21]. Moreover, Barrett cells were shown to
favour the more detrimental oxidative phenotype that may be se-
lected for during the early stages prior to disease progression [21].
Various studies linking energy metabolism with inﬂammation,
hypoxia and angiogenesis highlight how reciprocal processes act
jointly to signiﬁcantly alter the local microenvironment and atten-
uate disease progression [22–25]. However, despite recent insight
into energymetabolism proﬁles in Barrett oesophagus, less is known
about how energy metabolism and other key cellular processes co-
operate in the Barrett microenvironment. Interestingly, p53
overexpression is associated with an increased risk of neoplastic pro-
gression in patients with Barrett oesophagus, however, the risk is
greater with loss of p53 expression [26]. Moreover, in inﬂamed
Barrett oesophagus patients with progressive disease, oxidative-
induced damage results in telomere shortening and mutations in
the p53 gene abrogate p53’s role as the checkpoint of prolifera-
tion and apoptosis [27]. In addition to obesity and p53 status, the
length of the Barrett segment has been shown to be a risk factor
in the development of Barrett associated OAC [28–30].
The aim of this study was to examine the link between energy
metabolism, hypoxia, inﬂammation, p53 and obesity in the Barrett
tissue microenvironment in-vivo and ex-vivo. We report herein that
oxidative phosphorylation and p53 status positively correlated with
hypoxia. Moreover, levels of oxidative phosphorylation are posi-
tively linked to p53 expression whereas levels of glycolysis are
negatively associated with p53 expression. In addition, oxidative
phosphorylation and glycolysis are positively associated with in-
ﬂammation. Interestingly, we demonstrated that obesity was
negatively associated with oxidative phosphorylation but positive-
ly associated with glycolysis. Analogous correlations were exhibited
in ex-vivo explant tissue between metabolism, p53, hypoxia, in-
ﬂammation and angiogenesis.
Materials and methods
ATP5B, GAPDH, p53, IL1β, SERPINA3 and HIF1α immunohistochemical analysis using
tissue microarrays
Ethical approval to conduct all aspects of this work was granted by the Ad-
elaide and Meath Hospital (AMNCH), Tallaght, Dublin (REC 200110405). All cases
were prospectively recruited at our national referral centre for upper GI malignan-
cy and written informed consent was obtained in accordance with local institutional
ethical guidelines. All patients attending with histologically conﬁrmed Barrett oe-
sophagus were considered for inclusion. Patients with a prior history of dysplasia
or carcinoma, other malignancy of any type, or ablative therapy (radiofrequency ab-
lation, argon plasma coagulation, cryoablation) were excluded. Endoscopic
examination consisting of white light and chromoendoscopy (FICE (fujinon) or NBI
(olympus)) was performed in all cases (DOT and FMC). The Barrett segment was as-
sessed andmeasured as per the Prague classiﬁcation system and biopsied using large
capacity forceps.
Patients with intestinal metaplasia were identiﬁed from our Barrett tissue da-
tabase and immunohistochemistry was performed. Themedian age of patients (n = 29)
with intestinal metaplasia was 65 years, there was a 2.22-fold male predominance
and all patients were followed for a median of 7.5 years. The areas of interest on
the diagnostic biopsy blocks were marked by a pathologist. 0.6 mm cores were taken
from the blocks and tissue microarrays (TMAs) were constructed and pathology of
the tissue re-evaluated prior to antibody staining. Immunohistochemistry was per-
formed utilising the Vectastain Kit (Elite) as per manufacturer’s instructions. All tissue
microarray sections were processed and stained on the same day at room temper-
ature. Endogenous peroxidases were quenched in 3% hydrogen peroxide (inmethanol)
for 30 mins and slides blocked with serum for 30 mins. Primary antibodies used
were a mouse anti-ATP5B IgG (SantaCruz Biotechnology) (1:1000), a rabbit anti-
GAPDH IgG (AbDserotec Division of MorphoSys) (1:300), a rabbit anti-p53 IgG (Abcam)
(1:150), a rabbit anti-IL1β IgG (Abcam) (1:200), a rabbit anti-SERPINA3 IgG (Abcam)
(1:200) and a rabbit anti-HIF1α IgG (Abcam) (1:200) diluted in PBS. Staining was
undertaken with adequate negative controls (PBS only without primary antibody).
Slides were incubated with primary antibody for 1 hour, then biotinylated anti-
body for 30 minutes, avidin–biotin complex for 30 minutes and DAB substrate for
2–15 minutes. DAB was rinsed off slides upon colour development and haematoxylin
added for 30 seconds. Lastly, slides were dehydrated and mounted using DPX. Slides
were scanned (Philips Digital Pathology Solutions) and immunoreactivity was as-
sessed digitally under 40× magniﬁcation in a semi-quantitative manner for each
protein by observers who were blinded to the pathology of all patients in the study.
For each protein, both epithelial and stromal cells were evaluated for both percent-
age positivity and intensity of cytoplasmic staining. A third score, designated I × P,
was obtained by multiplying intensity by positivity. Intensity was graded as 0 (neg-
ative), 1 (weak), 2 (moderate) and 3 (strong) and positivity was evaluated as 0%, 10%,
25%, 50%, 75%, 90% or 100%. The scoring was undertaken by consensus evaluation
(JP and JOS) and the average value was calculated.
Expression of all protein markers was subsequently correlated to waist circum-
ference and to the length of the Barrett segment. Waist circumference and Barrett
segment length demographics were available on 15 and 22 patients respectively from
the 29 patients who participated in the study. 15 patients were used to assess the
link between ATP5B, GAPDH and waist circumference; the median age of patients
with intestinal metaplasia was 65 years, there was a 2.75-fold male predominance
and patients had a median waist circumference of 104 cm. 22 patients were used
to assess the link between ATP5B, GAPDH and the length of the Barrett segment;
the median age of patients (n = 22) with intestinal metaplasia was 61.5 years, there
was a 2.14-foldmale predominance and patients had amedian Barrett segment length
of 5 cm.
Assessing the effect of hypoxia in an in-vitro model of Barrett oesophagus
Cell culture
The QH (Barrett metaplasia) cell line was sourced from American Type Culture
Collection (ATCC) (LGC Standards, Middlesex, UK). QH cells were grown to 70%
conﬂuency in BEBMmedium supplementedwith BEBM SingleQuots (2mL BPE, 0.5mL
insulin, 0.5 mL HC, 0.5 mL GA-1000, 0.5 mL retinoic acid, 0.5 mL transferring, 0.5 mL
triiodothyronine, 0.5 mL adrenaline and 0.5 mL hEGF per 500 ml media). QH cells
were seeded 50,000 per well in 12 well plates and subsequently cultured under
normoxia (21% oxygen) and hypoxia (0.5%) conditions for 24 hours. RNA extrac-
tion was subsequently performed using RNeasy Mini Kit (Qiagen) following
manufacturer’s instructions. RNA content and quality was quantiﬁed and assayed
respectively (Nanodrop®, 8-Sample Spectrophometer, ND-800) and RNA reverse tran-
scribed using Bioscript enzyme (Bioline).
Gene expression analysis
Gene primer probes for VEGFA, ATP5B, p53, PKM2, IL1β, AMPK, GAPDH, HSP60,
mTOR and 18S (Applied Biosystems) were purchased and realtime PCR was per-
formed using Taqmanmastermix following manufacturer’s instructions on a 7900HT
Fast Realtime PCR Light-Cycler System (Applied Biosystems). PCR data was analysed
utilising the 2−ΔΔCt method [21]. First, threshold cycle (Ct) values were converted to
2−Ct in order to be proportional to the amount of transcripts in cell line samples.
Next, 2−ΔCt values were calculated by normalising the data to a housekeeping gene,
18S, as follows; 2−ΔCt = 2−Ct (QH 21%)/2−Ct (18S). In order to compare relative gene
expression between cells exposed to normoxia and hypoxia, 2−ΔΔCt values were cal-
culated by normalising the experimental data by reference data. For example, data
from one sample was normalised to another sample as follows: 2−ΔΔCt = 2−ΔCt (QH
21%)/2−ΔCt (QH 0.5%).
Assessment of secreted inﬂammatory and angiogenic markers
QH cell supernatant, previously exposed to normoxia and hypoxia conditions,
was screened for a panel of secreted inﬂammatory and angiogenic markers. The in-
ﬂammatory markers assessed were interleukin-10 (IL10), IL12p70, IL13, IL2, IL6, IL4,
IL8 and tumour necrosis factor alpha (TNFα). The angiogenic markers assessed were
angiopoietin 2 (ANG2), basic ﬁbroblast growth factor (bFGF), intracellular cell ad-
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hesion molecule-1 (ICAM-1), plasminogen activator inhibitor-1 (PAI-1), vascular cell
adhesion molecule-1 (VCAM-1) and VEGF (Meso Scale Discovery Multi-Array tech-
nology). Secreted lactate levels were additionally assessed (Sigma). All in-vitro data
was normalised to cell number using the crystal violet assay.
Barrett ex-vivo explant culture
All fresh ex-vivo Barrett intestinal metaplasia tissues were prospectively re-
cruited at our national referral centre for upper GI malignancy and obtained as above.
The median age of patients (n = 9) with intestinal metaplasia was 62 years and there
was an 8-fold male predominance. Barrett explant tissue was subsequently trans-
ferred into 1 mL M199 medium (10% FBS, 1% Pen/Strep, 1 mg/mL insulin) (Gibco)
and cultured for 24 hours at 5% CO2 at 37 °C. Following 24 hour incubation, the Barrett
conditioned medium was collected and explant tissues snap frozen in liquid nitro-
gen. Both media and tissue were stored at −80 °C for future use.
Ex-vivo qRT-PCR analysis
Barrett explant tissue was homogenised using a Tissue-Lyser (Qiagen) for 2.5min
at a frequency of 25 pulses per second, RNA and protein extracted simultaneously
(Qiagen), RNA quantiﬁed and RNA quality assessed (Nanodrop®, 8-Sample
Spectrophometer, ND-800). RNA was reverse transcribed using Bioscript enzyme
(Bioline). Gene primer probes for ATP5B, HSP60, GAPDH, PKM2, p53, HIF1A and 18S
(Applied Biosystems) were purchased and realtime PCRwas performed using Taqman
mastermix (Applied Biosystems). Data was analysed utilising the 2−ΔΔCt method as
above. All 9 Barrett explant tissue was characterised by assessing the expression of
the columnar epithelium molecular marker villin using RT-PCR; all Barrett explant
tissue was positive for the presence of villin and all matched adjacent normal squa-
mous tissues were negative for villin.
Ex-vivo MSD multiplex ELISA analysis
Barrett conditioned medium was screened for the levels of the multiplex in-
ﬂammatory and angiogenic proteins (Meso Scale Discovery Multi-Array technology).
The inﬂammatory proteins assessed were GRO-alpha (GROα), IL1β, IL10, IL2, IL6,
monocyte chemoattractant protein-1 (MCP-1), macrophage inﬂammatory protein
3 alpha (MIP3α), matrix metallopeptidase 2 (MMP2), MMP9 and TNFα. The angio-
genic proteins assessed were ANG1, bFGF, PAI-1, ICAM-1, VCAM-1 and VEGF. Secreted
lactate levels were also assessed in the Barrett conditioned medium. Subsequent to
screening for these secreted inﬂammatory and angiogenic proteins, HIF1α and p53
expression levels were evaluated through RT-qPCR and all factors were subse-
quently correlated to metabolism (ATP5B, HSP60, GAPDH and PKM2) at the gene level.
Total protein extracted above (Qiagen) was assayed utilising a bicinchoninic acid assay
(Thermo Scientiﬁc) and secreted protein levels of these secreted factors in all samples
were normalised to total protein.
Statistical analysis
Data was analysed using Graph Pad Prism software (Graph Pad Prism, San Diego,
CA). Paired t-tests were utilised to assess if hypoxia had a metabolic or inﬂamma-
tory effect using the in-vitro QH Barrett cell line at the gene and protein level. In-
vivo immunohistochemical expression proﬁles of ATP5B and GAPDHwere correlated
to p53, IL1β, SERPINA3, HIF1α, waist circumference and to the length of the Barrett
segment using Spearman ρ analyses. Multiple regression analyses were undertak-
en to investigate associations between two factors taking into account other factors
in-vivo (R statistical software, package ‘abn’). In addition, additive Bayesian net-
works were implemented to assess the dependencies between factors taking into
account the combined effect of all factors in-vivo (R statistical software, package ‘abn’).
Majority consensus was constructed over 5000 iterations to select a best-ﬁtting
network representation of the relations between markers. Secreted protein levels
and gene expression levels in ex-vivo explant tissue were correlated similarly (Spear-
man ρ correlation). Moreover, BMI was correlated to all ex-vivo factors (Spearman
ρ correlation). Differences of P < 0.05 (*), P < 0.01 (**) and P < 0.001 (***) were con-
sidered statistically signiﬁcant.
Results
Linking energy metabolism, p53 and inﬂammation in the Barrett
tissue microenvironment in-vivo
To assess oxidative phosphorylation and glycolysis at the protein
level, levels of ATP5B and GAPDH respectively were assessed in in-
vivo Barrett patient tissue. Fig. 1 shows immunohistochemical
expression of these metabolic markers and investigates the link
between energy metabolism and p53 in the Barrett tissue microen-
vironment. ATP5B intensity is positively correlatedwith p53 intensity
in the epithelium (Fig. 1A) (r = 0.53, P = 0.0031). This association,
illustrated by representative images, shows that tissue from Barrett
patients exhibiting low p53 expression (Fig. 1C) showed low ATP5B
intensity (Fig. 1E), however, low p53 expression was associated with
high I × P GAPDH expression levels (Fig. 1G). Stromal GAPDH I × P
expression signiﬁcantly negatively correlated to p53 I × P expres-
sion (Fig. 1B) (r = −0.39, P = 0.0357). This association, illustrated by
representative images, shows that Barrett patients exhibiting high
p53 expression (Fig. 1D) displayed high ATP5B intensity (Fig. 1F),
however, high p53 expression was associated with low I × P GAPDH
expression levels (Fig. 1H).
Fig. 2 investigates the relationship between p53 and inﬂamma-
tion in the Barrett tissue microenvironment. IL1β I × P expression
signiﬁcantly positively correlated to levels of p53 I × P expression
in the epithelium (Fig. 2A) (r = 0.43, P = 0.02). This association, il-
lustrated by representative images, shows that Barrett patients
exhibiting low epithelial p53 expression (Fig. 2C) demonstrated low
I × P IL1β expression (Fig. 2E) and low SERPINA3 positivity levels
(Fig. 2G). SERPINA3 positivity signiﬁcantly positively correlated to
p53 positivity in the epithelium (Fig. 2B) (r = 0.536, P = 0.0033). This
association, illustrated by representative images, shows that Barrett
patients exhibiting high epithelial p53 expression (Fig. 2D) dis-
played high I × P IL1β expression (Fig. 2F) and high SERPINA3 (Fig. 2H)
positivity levels.
Next, the association between energy metabolism and inﬂam-
mation in the Barrett tissue microenvironment was investigated.
Fig. 3 investigates the association between energy metabolism and
inﬂammation in the Barrett tissue microenvironment. Epithelial
ATP5B positivity signiﬁcantly positively correlated to epithelial IL1β
positivity (Fig. 3A) (r = 0.8, P < 0.0001). Furthermore, epithelial GAPDH
positivity signiﬁcantly positively correlated to epithelial IL1β posi-
tivity (Fig. 3B) (r = 0.43, P = 0.022). In addition, GAPDH expression
did not signiﬁcantly correlate to levels of SERPINA3 in the epithe-
lium, however, ATP5B I × P expression did signiﬁcantly correlate to
I × P expression levels of SERPINA3 in the epithelium (r = 0.66,
P = 0.0001) (data not shown).
Linking hypoxia to energy metabolism, inﬂammation and p53 in
Barrett oesophagus in-vitro and in-vivo
Firstly, to investigate if hypoxia is potentially associated withme-
diating energy metabolism and inﬂammation, QH cells, an in-vitro
model of an intestinal metaplasia culture, were exposed to normoxic
(21% oxygen) and hypoxic (0.5% hypoxia) conditions. Levels of
genomic ATP5B (Fig. 4A), GAPDH (Fig. 4B), PKM2 (Fig. 4C), VEGFA
(Fig. 4D) and IL1β (Fig. 4E) were signiﬁcantly differentially ex-
pressed in Barrett QH cells under normoxic and hypoxic conditions.
In addition, secreted levels of lactate (Fig. 4F), VEGF (Fig. 4G), IL-8
(Fig. 4H) and PAI-1 (Fig. 4I) were differentially altered in those Barrett
cells exposed to normoxia (21% oxygen) and hypoxia (0.5% hypoxia).
Hypoxia was shown to signiﬁcantly affect cell viability (see
Supplementary Fig. S1). As we found differential hypoxia-induced
alterations in various metabolic and inﬂammatory proﬁles in-
vitro, we next investigated the affect of hypoxia in-vivo.
To assess if the relationship between hypoxia and these cellular
processes can be recapitulated in-vivo, protein levels of HIF1αwere
assessed. Fig. 5 investigates the effect of hypoxia on energy metab-
olism, inﬂammation andp53 in the Barrett tissuemicroenvironment.
Focusing on the exact same area within the Barrett tissue, Barrett
patientswith low I × PHIF1α expression (Fig. 5A) exhibited low I × P
expression levels of ATP5B (Fig. 5C). Similarly, patients with high
HIF1α I × P expression (Fig. 5B) exhibited high I × P expression levels
of ATP5B (Fig. 5D). HIF1α I × P expression signiﬁcantly positively cor-
related to ATP5B I × P expression in the epithelium (Fig. 5E) (r = 0.71,
P < 0.0001). However, HIF1α I × P expression (r = 0.06, P = 0.7) did
not signiﬁcantly correlate to levels of GAPDH I × P expression in the
epithelium as shown in Fig. 5F. HIF1α I × P expression signiﬁcantly
336 J.J. Phelan et al./Cancer Letters 371 (2016) 334–346
positively correlated to levels of SERPINA3 I × P expression in the
epithelium (Fig. 5G) (r = 0.522, P = 0.0044). Epithelial HIF1α I × P ex-
pression signiﬁcantly positively correlated to levels of epithelial p53
I × P expression (Fig. 5H) (r = 0.455, P = 0.015).
Linking energy metabolism to obesity and to the length of the Barrett
segment in the Barrett tissue microenvironment in-vivo
Fig. 6 investigates the link between energy metabolism, obesity
and the length of the Barrett segment in the Barrett tissue
microenvironment. Stromal ATP5B I × P expression signiﬁcantly neg-
atively correlated to waist circumference (Fig. 6A) (r = −0.6016,
P = 0.0177). Epithelial GAPDH intensity signiﬁcantly positively cor-
related to waist circumference (Fig. 6B) (r = 0.743, P = 0.0015).
ATP5B and GAPDH were also correlated to the length of the
Barrett segment. Stromal GAPDH intensity signiﬁcantly positively
correlated to the length of the Barrett segment (Fig. 6C) (r = 0.5192,
P = 0.0133), however, ATP5B did not. Note that no additional sta-
tistically signiﬁcant associations were found in-vivo between all
protein markers within the stromal compartment (data not shown).
Fig. 1. The link between energy metabolism and p53 in Barrett oesophagus in-vivo. (A) Epithelial ATP5B intensity signiﬁcantly positively correlated to epithelial p53 in-
tensity (r = 0.53, P = 0.0031). (B) GAPDH I × P expression signiﬁcantly negatively correlated to levels of p53 I × P expression in the stroma (r = −0.39, P = 0.0357). (C) Barrett
patients displaying low levels of p53 expressed low intensity levels of ATP5B (E) and high I × P expression levels of GAPDH (G) respectively. (D) Barrett patients displaying
high levels of p53 expressed high intensity levels of ATP5B (F) and low I × P expression levels of GAPDH (H) respectively. r denotes Spearman ρ correlation (I × P = intensity
by positivity).
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Importantly, to ascertain a more comprehensive understand-
ing between factors without the inﬂuence of other endogenous
factors in-vivo, multiple regression analyses were undertaken. Table 1
compares the associations between metabolism, inﬂammation,
hypoxia, p53 obesity and the length of the Barrett segment in-
vivo using both Spearman ρ andmultiple regression analyses. ATP5B
was signiﬁcantly associated with p53 (P = 0.03), IL1β (P = 0.019) and
HIF1α (P = 0.002). GAPDH was signiﬁcantly linked with p53
(P = 0.007) and waist circumference (P = 0.003). All other pairings
did not reach statistical signiﬁcance. In addition, construction of Ad-
ditive Bayesian Networks from multiple regressions showed some
evidence of interdependencies between markers (data not shown).
Linking energy metabolism to p53, inﬂammation, hypoxia and
angiogenesis in the Barrett tissue microenvironment ex-vivo
To elucidate the relationship between energy metabolism and
these processes, we used Barrett ex-vivo explant tissue in an effort
to utilise a model that mimicked the Barrett tissue microenviron-
ment linking gene expression proﬁles and protein secretion proﬁles
associated with the above cellular processes. Table 2 summarises
the association betweenmetabolism and inﬂammation, hypoxia, p53
and angiogenesis in Barrett ex-vivo explant tissue. ATP5B expres-
sion signiﬁcantly positively correlated to TNFα (r = 0.79, P = 0.027),
IL6 (r = 0.93, P = 0.002), HIF1α (r = 0.88, P = 0.003) and p53 (r = 0.72,
Fig. 2. Linking p53 and inﬂammation in Barrett oesophagus in-vivo. (A) Epithelial IL1β I × P expression signiﬁcantly positively correlated to levels of epithelial p53 I × P ex-
pression (r = 0.43, P = 0.02). (B) SERPINA3 positivity signiﬁcantly positively correlated to p53 positivity in the epithelium (r = 0.536, P = 0.0033). (C) Barrett patients displaying
low epithelial levels of p53 expressed low epithelial I × P expression levels of IL1β (E) and low epithelial positivity levels of SERPINA3 (G). (D) Barrett patients displaying
high epithelial levels of p53 expressed high epithelial I × P expression levels of IL1β (F) and high epithelial positivity levels of SERPINA3 (H). r denotes Spearman ρ corre-
lation (I × P = intensity by positivity).
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P = 0.037). HSP60 expression was signiﬁcantly positively associ-
ated with HIF1α (r = 0.73, P = 0.031). GAPDH expression signiﬁcantly
positively correlated to TNFα (r = 0.81, P = 0.021), IL6 (r = 0.9,
P = 0.004) and HIF1α (r = 0.87, P = 0.002). PKM2 expression signiﬁ-
cantly positively correlated to IL6 (r = 0.73, P = 0.025),HIF1α (r = 0.92,
P = 0.001) and p53 (r = 0.9, P = 0.002). Moreover, HSP60 (r = −0.7,
P = 0.036) and PKM2 (r = −0.68, P = 0.042) were signiﬁcantly nega-
tively associated with angiogenesis (ANG-1). No signiﬁcant
correlations were found with secreted lactate levels (P > 0.05).
Linking inﬂammation, hypoxia, p53, BMI and angiogenesis in the
Barrett tissue microenvironment ex-vivo
Table 3 summarises the link between inﬂammation, hypoxia, p53,
BMI and angiogenesis in the Barrett ex-vivo explant tissue. Angio-
genesis (ICAM-1) signiﬁcantly positively correlated toMCP-1 (r = 0.76,
P = 0.036), MMP9 (r = 0.72, P = 0.03), IL2 (r = 0.78, P = 0.013) and TNFα
(r = 0.79, P = 0.028). In addition, secreted levels of bFGF signiﬁ-
cantly positively correlated to IL1β (r = 0.76, P = 0.036) and IL10
(r = 0.71, P = 0.047). Moreover, BMI signiﬁcantly positively corre-
lated to secreted levels of VCAM-1 (r = 0.8, P = 0.01), ICAM-1 (r = 0.73,
P = 0.025) and ANG1 (r = 0.72, P = 0.03). HIF1α signiﬁcantly posi-
tively correlated to expression levels of p53 (r = 0.88, P = 0.003), GROα
(r = 0.75, P = 0.025), IL6 (r = 0.88, P = 0.003), MIP3α (r = 0.75, P = 0.025),
MMP2 (r = 0.81, P = 0.022), TNFα (r = 0.72, P = 0.037) and IL1β (r = 0.67,
P = 0.049). Furthermore, p53 status signiﬁcantly positively corre-
lated with IL6 (r = 0.75, P = 0.025) and MMP2 (r = 0.76, P = 0.037).
Discussion
An understanding of the complex processes in the inﬂamma-
tion to tumour model of Barrett oesophagus and OAC may provide
some insight into both biomarkers of risk progression, and the po-
tential for the development of novel targeted therapies. We have
shown for the ﬁrst time that mitochondrial energy metabolism is
strongly associated with inﬂammation and hypoxia in the Barrett
oesophagus tissue microenvironment. The study also highlights that
mitochondrial energymetabolism is aligned with p53 status, obesity
status and to the length of the Barrett segment, further demon-
strating that various cellular mechanisms may operate
interdependently fuelling progression within the Barrett microen-
vironment to HGD and OAC.
To assess oxidative phosphorylation and glycolysis respective-
ly, levels of the protein markers ATP5B and GAPDH were assessed
as increased ATP5B and GAPDH is known to be associated with neo-
plastic progression across the Barrett disease sequence [21]. Levels
of ATP5B and GAPDH are commonly used as surrogate markers of
both oxidative phosphorylation and glycolysis [21,31–35]. The ab-
errant expression of the tumour suppressor protein, p53, commonly
associated with aneuploidy is associated with an increased risk of
neoplastic progression in Barrett oesophagus [26]. In this study, we
have shown in-vivo and ex-vivo that ATP5B, a marker of oxidative
phosphorylation, was signiﬁcantly positively correlated to p53 status
in Barrett oesophagus. We also demonstrate in-vivo that GAPDH, a
marker of glycolysis, was signiﬁcantly negatively associated with
p53. At the gene level ex-vivo, p53 was shown to be positively as-
sociated with another marker of glycolysis, PKM2. p53 has an
important role in cellular metabolism, lowering glycolysis, an anti-
Warburg affect, and promoting oxidative phosphorylation [9,36–38].
p53 promotes oxidative phosphorylation through the p53-inducible
protein Mieap and also through the master transcription regula-
tor nuclear factor kappa B (NFκB)-mediated upregulation of
mitochondrial synthesis of cytochrome c oxidase 2 (SCO2) [39,40].
p53 negatively regulates glycolysis by downregulating key compo-
nents of glycolysis such as glucose transporter 1 (GLUT1), GLUT3,
phosphofructose kinase 1 and PKM2 [9,41–43]. It may be plausi-
ble that the increased oxidativemicroenvironment that p53 promotes
in Barrett oesophagus supports metaplastic progression as one study
has found that oxidative-induced damage in Barrett patients results
in telomere shortening and mutations in the p53 gene itself [27].
Therefore, with an oxidative-induced abrogation of p53 function,
glycolytic levels are no longer negatively regulated and this may
explain why levels of glycolysis may increase early in the progres-
sion of OAC [21]. Alternatively, p53 may simultaneously promote
oxidative phosphorylation, producing large amounts of ATP and
shunt high energy glycolytic intermediates into the pentose phos-
phate pathway [44]. The NFκB family member RelA is transported
intomitochondria and recruited to themitochondrial genomewhere
it can repress mitochondrial gene expression, oxygen consump-
tion and cellular ATP levels, thereby contributing to the switch to
glycolysis. Conversely, upon low cellular ATP levels, NFκB can
upregulate mitochondrial respiration through SCO2, a key compo-
nent of complex IV of the electron transport chain [40]. Despite some
evidence in glioma cells suggesting that p53 localisation is associ-
ated with p53 mutational status, whether mutant p53 localises to
the cytoplasm and mediates cellular function and metabolism war-
rants future investigation in the setting of Barrett oesophagus and
in other preneoplastic and neoplastic tissues [45].
Few studies have investigated the direct association between oxi-
dative phosphorylation and inﬂammation. NFκB is a key
inﬂammatory mediator of both oxidative phosphorylation and gly-
Fig. 3. The association between energy metabolism and inﬂammation in Barrett oe-
sophagus in-vivo. (A) Epithelial ATP5B positivity signiﬁcantly positively correlated
to epithelial IL1β positivity (r = 0.8, P < 0.0001). (B) Epithelial GAPDH positivity sig-
niﬁcantly positively correlated to epithelial IL1β positivity (r = 0.43, P = 0.022).
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colysis, and promotes IL1β and TNFα production [40,42,46]. To assess
inﬂammation, levels of the inﬂammatorymarkers IL1β and SERPINA3
were assessed. IL1β and SERPINA3 have previously been utilised as
markers of inﬂammation and have previously been identiﬁed as
playing an important role in neoplastic progression [9,47–52]. In
this study, ATP5B was signiﬁcantly positively correlated to levels
of IL1β and SERPINA3 in-vivo, and with TNFα and IL6 in Barrett ex-
vivo explant tissue. Furthermore, GAPDHwas signiﬁcantly positively
correlated to levels of IL1β, TNFα and IL6 in in-vivo and ex-vivo Barrett
tissue. IL1β, IL6 and TNFα may have key roles in the development
and subsequent progression of OAC, consistent with a murine model
where overexpression of IL1β induced intestinal metaplasia and OAC,
an effect abrogated by IL6 deﬁciency [9]. In this context, the effec-
tor functions of IL1β-dependent TH17 cells have been shown to be
related to their glycolytic capacity [53]. TNFα has also been shown
to stimulate glycolysis in colorectal cancer cells [24]. Moreover, in-
creased expression of the key glycolytic enzymes, 6-phosphofructo-
2-kinase/fructose-2,6-bisphosphatase-3 and hexokinase 2, have been
shown to be orchestrated by the IL6-STAT3 pathway further pro-
viding a mechanism for inﬂammation-associated oncogenesis in
Barrett oesophagus [54]. Inﬂammation is also known tomediateme-
tabolism through NFκB in a p53-dependent manner [40,46].
Hypoxia and related genes, and their interface with inﬂamma-
tion and metabolism, are also relevant to this model. Subsequent
to demonstrating differential hypoxia-induced effects on inﬂam-
mation, angiogenesis and metabolism in-vitro, we found that both
oxidative phosphorylation (ATP5B and HSP60) and glycolysis (GAPDH
and PKM2) signiﬁcantly positively correlated to HIF1α at the gene
level ex-vivo and in-vivo ATP5B protein levels signiﬁcantly posi-
tively correlated with HIF1α protein expression; however, HIF1α
showed no correlation with GAPDH. Interestingly, various studies
in the cancer setting have implicated glycolysis as one of the main
distinctive factors in the adaptation to hypoxic stress, as hypoxia
mediates metabolism by inducing the expression of various glyco-
lytic components [55]. No studies to our knowledge have showed
such a strong positive association between hypoxia and oxidative
Fig. 4. Investigating the effect of hypoxia on metabolic, inﬂammatory and angiogenic proﬁles in an in-vitro model of Barrett oesophagus. Levels of genomic ATP5B (A), GAPDH
(B), PKM2 (C), VEGFA (D) and IL1β (E) were signiﬁcantly differentially expressed in Barrett cells exposed to normoxia (21% oxygen) and hypoxia (0.5% hypoxia). Secreted
levels of lactate (F), VEGF (G), IL-8 (H) and PAI-1 (I) were found to be differentially altered in Barrett cells exposed to normoxia (21% oxygen) and hypoxia (0.5% hypoxia).
(*P < 0.05, **P < 0.01; paired t-test; n = 3–7).
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phosphorylation in the preneoplastic or neoplastic setting. Even
though this adaptation to oxidative phosphorylation results in the
production of large amounts of ATP produced per glucose mole-
cule compared to glycolysis, it is plausible, however, that this positive
relationship reﬂectsmore of an indirect relationship between hypoxia
and other complex constitutive processes in the Barrett microen-
vironment, such an inﬂammation and p53 status. Therefore, we
investigated if there was an association between hypoxia, inﬂam-
mation and p53 status in Barrett tissuemicroenvironment.We found
that hypoxia signiﬁcantly positively correlated to levels of p53 in-
Fig. 5. Linking hypoxia to energy metabolism, inﬂammation and p53 in Barrett oesophagus in-vivo. (A) A Barrett patient, displaying low I × P expression levels of HIF1α
also expressed low epithelial I × P expression levels of ATP5B (C) within the same tissue area of the Barrett tissue microenvironment. (B) A Barrett patient, displaying high
epithelial I × P expression levels of HIF1α also expressed high epithelial I × P expression levels of ATP5B (D) within the same tissue area of the Barrett tissue microenviron-
ment. (E) Epithelial ATP5B I × P expression signiﬁcantly positively correlated to levels of epithelial HIF1α I × P expression (r = 0.71, P < 0.0001). (F) HIF1α I × P expression did
not correlate to levels of GAPDH I × P expression in the epithelium (r = 0.06, P = 0.7). (G) HIF1α I × P expression signiﬁcantly positively correlated to levels of SERPINA3 I × P
expression in the epithelium (r = 0.522, P = 0.0044). (H) p53 I × P expression signiﬁcantly positively correlated to levels of HIF1α I × P expression in the epithelium (r = 0.455,
P = 0.015). r denotes Spearman ρ correlation (I × P = intensity by positivity).
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vivo and ex-vivo. No studies to our knowledge have linked hypoxia
to p53 in the Barrett setting. Some studies, however, have shown
p53 to encompass an important role in hypoxic microenviron-
ments [56,57]. Under hypoxic conditions, the p53-inducible
phosphatase, TP53-induced glycolysis and apoptosis regulator, forms
a complex with hexokinase 2 at the mitochondria [56]. This complex
subsequently shunts glycolytic intermediates into the pentose phos-
phate pathway reducing glycolytic ﬂux and generating NADPH,
ribose-5-phosphate and erythrose-4-phosphate for the production
of fatty acids, nucleotides, nucleic acids and amino acids [56]. In the
neoplastic setting, suppression of HIF2α has been shown to restore
p53 activity reversing chemoresistance in renal carcinoma cells [57].
Moreover, it is also noteworthy to mention that making direct com-
parisons between the in-vitro Barrett cell line and the in-vivo and
ex-vivo tissue would be inaccurate as they are biologically differ-
Fig. 6. Linking energymetabolism to obesity and to the length of the Barrett segment
in Barrett oesophagus in-vivo. (A) Stromal ATP5B I × P expression signiﬁcantly neg-
atively correlated towaist circumference (r = −0.6016, P = 0.0177). (B) Epithelial GAPDH
intensity signiﬁcantly positively correlated to waist circumference (r = 0.743,
P = 0.0015). (C) Stromal GAPDH intensity signiﬁcantly positively correlated to the
length of the Barrett segment (r = 0.5192, P = 0.0133). Waist circumference and Barrett
segment length demographics were available on 15 and 22 patients respectively from
the 29 patients who participated in the study. r denotes Spearman ρ correlation
(I × P = intensity by positivity).
Table 1
Comparing the association betweenmetabolism, inﬂammation, hypoxia, p53, obesity
and the length of the Barrett segment in-vivo using Spearman ρ and multiple re-
gression analyses.
Spearman Correlation Multiple Regression
Correlation r† P Estimate P
Metabolism vs p53
ATP5B vs p531A 0.53 0.0031 0.3847 0.03
GAPDH vs p533B −0.39 0.0357 −3.78245 0.007
p53 vs Inﬂammation
p53 vs IL1β3A 0.43 0.02 −0.1452 0.464
p53 vs SERPINA32A 0.536 0.0033 0.1397 0.537
Metabolism vs Inﬂammation
ATP5B vs IL1β2A 0.8 <0.0001 0.5118 0.019
GAPDH vs IL1β2A 0.43 0.022 0.155 0.378
Metabolism vs Hypoxia
ATP5B vs HIF1α3A 0.71 <0.0001 0.4838 0.002
GAPDH vs HIF1α3A 0.06 0.7 −0.24441 0.112
Hypoxia vs Inﬂammation
HIF1α vs SERPINA33A 0.522 0.0044 0.08036 0.744
p53 vs Hypoxia
p53 vs HIF1α3A 0.455 0.015 0.1915 0.253
Metabolism vs Waist Circumference
ATP5B3B vs Waist
Circumference
−0.6016 0.0177 −0.89 0.399
ATP5B3A vs Waist
Circumference
−0.354 0.195 −2.19 0.059
GAPDH1A vs Waist
Circumference
0.743 0.0015 49.06 0.003
Metabolism vs Length of Barrett’s Segment
GAPDH1B vs Barrett Segment 0.5192 0.0133 6.0504 0.181
† Correlation Coeﬃcient (r).
1 Intensity.
2 Positivity.
3 Intensity × Positivity.
A Epithelium.
B Stroma.
Table 2
The association between metabolism and inﬂammation, hypoxia, p53 and angio-
genesis in Barrett ex-vivo explant tissue.
Correlation Correlation Coeﬃcient, r P
Metabolism vs Inﬂammation
ATP5B vs TNFα* 0.79 0.027
ATP5B vs IL6* 0.93 0.002
GAPDH vs TNFα* 0.81 0.021
GAPDH vs IL6* 0.9 0.004
PKM2 vs IL6 0.73 0.025
Metabolism vs Hypoxia
ATP5B vs HIF1α 0.88 0.003
HSP60 vs HIF1α 0.73 0.031
GAPDH vs HIF1α 0.87 0.002
PKM2 vs HIF1α 0.92 0.001
Metabolism vs p53
ATP5B vs p53 0.72 0.037
PKM2 vs p53 0.9 0.002
Metabolism vs Angiogenesis
HSP60 vs ANG1 −0.7 0.036
PKM2 vs ANG1 −0.68 0.042
Spearman ρ, n = 9 (n = 8*).
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ent; in-vivo and ex-vivo tissue is complex primarily due to their rich
cell diversity, however, the Barrett cell line are solely epithelial cells.
We have further demonstrated that hypoxia signiﬁcantly posi-
tively correlated with inﬂammation in the Barrett setting in-vivo.
Ex-vivo, we illustrate that HIF1α is positively associated with various
secreted inﬂammatory proteins including GROα, IL6, MIP3α, MMP2,
MMP9, TNFα and IL1β. HIF1α protein expression has previously been
documented to be associated with inﬂammation in Barrett oe-
sophagus, however, this study utilised the Sydney System to assess
inﬂammation and not an inﬂammatory molecular marker analo-
gous to this current study [7]. Another study found increased
expression of the hypoxia-inducible proteins across the metaplasia-
dysplasia-OAC sequence in-vivo [6]. Therefore, the greater degree
of inﬂammation known to be associated with the latter stages of
the Barrett sequence may in part be hypoxia-induced inﬂamma-
tion in origin [58,59]. Moreover, T-cells are known to play an
important role in the initiation and subsequent progression of Barrett
oesophagus [60]. Interestingly, hypoxia is known to stimulate in-
creased levels of IL1β, IL10 and IL8 in human CD4+ T cells, but the
absence of glucose reduces secretions of these cytokines implying
that CD4+ T cells can be highly metabolically adaptable in highly
ﬂuctuating bioenergetic microenvironments [61]. Since both oxi-
dative phosphorylation and glycolysis were found to be strongly
associated with increased inﬂammation in the Barrett tissue mi-
croenvironment in this study, hypoxia-induced secretions of various
pro-inﬂammatory proteins may in theory alter the metabolic proﬁle
in the Barrett microenvironment. In addition to its close link with
hypoxia, we have shown in-vivo that p53 signiﬁcantly positively cor-
related with both IL1β and SERPINA3 in Barrett oesophagus. Ex-
vivo, we illustrate positive links between p53, IL6 and MMP2. Few
studies have linked p53 to IL1β and SERPINA3 in the literature but
p53’s role in the regulation of the key central inﬂammatory andmet-
abolic regulator, NFκB, has been documented [42,46]. Consequently,
the intrinsic relationship between hypoxia, inﬂammation and p53
early in the Barrett microenvironment may be suﬃcient to mediate
metabolism in support of metaplastic transformation.
Obesity is strongly associated with the increase in incidence of
Barrett oesophagus and OAC [13,14]. Detailed studies of the Barrett
and tumour microenvironment in this model are, however, scarce;
therefore, we assessed if there was an association between obesity
and both oxidative phosphorylation and glycolysis in our Barrett
cohort. Interestingly, we found a signiﬁcant negative association
between waist circumference and ATP5B expression but a signiﬁ-
cant positive association between waist circumference and GAPDH
expression. No studies have shown such a reciprocal association
between obesity and metabolism in preneoplastic or cancer tissue.
It is possible, however, that such obesity-induced metabolic altera-
tions are the functional result of various adipokines known to be
secreted by adipose tissue [62]. The fatty acid, palmitic acid, has been
shown to increase concentrations of fructose 2,6-biphosphate, a key
glycolytic intermediate [63]. Obesity has also been shown to promote
aerobic glycolysis in prostate cancer cells [64]. Conversely, a high
fat diet has been shown to downregulate genes required for oxi-
dative phosphorylation [65]. Moreover, after a 6-month exercise
programme, extensive alterations in the transcriptome proﬁle of
healthy human adipose tissue has shown increases in a variety of
genes associated with oxidative phosphorylation [66]. Adiponectin
is also known to promote mitochondrial biogenesis [67]. Serum
adiponectin levels are known to decline with obesity in Barrett oe-
sophagus which may decrease mitochondrial biogenesis in the
process [62]. In addition, it has also been shown that a palmitic acid-
induced decrease in adiponectin is responsible for mitochondrial
dysfunction in adipocytes [68]. The degree of glycolysis may also
depend on the oxidative capacity of the tissue, thus, increases in
glycolysis may be a compensatory mechanism as oxidative metab-
olism is inhibited. To support this, when we inhibit oxidative
phosphorylation in in-vitro Barrett cells utilising Seahorse technol-
ogy, we see a signiﬁcant compensatory increase in glycolytic levels
(see Supplementary Fig. S2). We also found a signiﬁcant positive cor-
relation between GAPDH and the length of the Barrett segment,
previously linked to metaplastic progression in Barrett oesopha-
gus [28–30].
Angiogenesis, a key hallmark of cancer, is linked to hypoxia and
glycolysis and therefore is key to endothelial cell function [22]. We
found that both HSP60 and PKM2 were signiﬁcantly negatively as-
sociated with the angiogenesis marker, ANG1, in Barrett ex-vivo
explant tissue. Although angiogenesis is positively associated with
neoplastic progression in some disease entities, these ﬁndings may
have some signiﬁcant physiological implications; that is, high energy
levels are associated with low angiogenic potential and low energy
levels are associated with high angiogenic potential. In addition, we
found ex-vivo that angiogenesis (ICAM-1 and bFGF) signiﬁcantly pos-
itively correlated with levels of inﬂammation (MCP1, MMP9, IL2,
TNFα, IL1β and IL10). Moreover, angiogenesis (ICAM-1, VCAM-1 and
ANG1) signiﬁcantly positively correlated with BMI status ex-vivo.
Overall, the in-vivo and ex-vivo ﬁndings in this study, as de-
picted in Fig. 7, effectively demonstrate the complexity of the cellular
processes of the Barrett tissuemicroenvironment and give an insight
into how these processes could potentially supportmetaplastic pro-
gression through the alterationof cellular energymetabolism.Despite
showing links between speciﬁc markers in this study, these links
represent the associations between the processes themselves and
not the markers; therefore, future studies need to address the mo-
lecular mediators linking these processes. However, it is plausible
that markers do regulate other markers in this study as evidenced
by previous studies [69–72]. Identifying and exploring the under-
lyingmolecularmechanisms that linkmetabolismto thesekeycellular
processes, and to each other, would signiﬁcantly aid in understand-
ing how these processes interact andmay provide some insight into
the development of targeted therapies inﬂuencing these processes.
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Fig. 7. The Barrett oesophagus microenvironment. The inﬂamed specialised intestinal metaplasia of Barrett oesophagus demonstrates many complex interdependencies.
Within epithelial and stromal cells, p53 positively associates with ATP5B but negatively with GAPDH. p53 positively correlates with IL1β and SERPINA3. Both ATP5B and
GAPDH are positively linked with IL1β, TNFα and IL6. p53 expression positively correlates with HIF1α expression. HIF1α expression positively correlates with ATP5B, PKM2
and SERPINA3. HSP60 and PKM2 negatively associate with ANG1, a marker of angiogenesis. Obesity status positively links with GAPDH but negatively with ATP5B. Obesity
positively correlates with angiogenesis. Inﬂammation and angiogenesis are additionally interdependent.
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